Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 May 26;211(2):216–225. doi: 10.1093/infdis/jiu307

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

PMC Copyright notice

Figure 6. — 54G10 neutralization of respiratory syncytial virus (RSV). A, 54G10 binds to RSV, as revealed by immunofluorescent assay. B, 54G10 neutralizes RSV in vitro. Brackets represent the standard error of the mean. Palivizumab neutralizes RSV, but DS7 does not. C, Prophylactic 54G10 decreases virus titer in the lungs, compared with control (***P < .001). D, Therapeutic 54G10 decreases lung virus titer, compared with control (***P < .001). Virus titer was log₁₀ transformed and analyzed by analysis of variance with the post-hoc Dunnett multiple comparisons test. Abbreviations: mAb, monoclonal antibody; PFU, plaque-forming unit.